Inmed announces results of 2022 annual general meeting

Vancouver, british columbia, dec. 15, 2022 (globe newswire) -- inmed pharmaceuticals inc. (“inmed” or the “company”) (nasdaq: inm), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today confirmed that, at its annual general meeting of shareholders held on december 15, 2022 (the “meeting”), all of the matters put forward before shareholders for consideration and approval as set out in inmed's notice of meeting and management information circular, dated october 28, 2022, were approved by the shareholders. in particular, shareholders approved the election of all director nominees to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. results of the vote for the election of directors at the meeting are set out as follows:
INM Ratings Summary
INM Quant Ranking